| 000 | 01691 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514163605.0 | ||
| 264 | 0 | _c20040428 | |
| 008 | 200404s 0 0 eng d | ||
| 022 | _a0197-2456 | ||
| 024 | 7 |
_a10.1016/s0197-2456(03)00096-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBots, Michiel L | |
| 245 | 0 | 0 |
_aThe Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. _h[electronic resource] |
| 260 |
_bControlled clinical trials _cDec 2003 |
||
| 300 |
_a752-75 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aCarotid Arteries _xdiagnostic imaging |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEstrogens, Conjugated (USP) _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNorpregnenes _xpharmacology |
| 650 | 0 | 4 |
_aOsteoporosis _xpathology |
| 650 | 0 | 4 |
_aPostmenopause _xdrug effects |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 |
_aRandomized Controlled Trials as Topic _xmethods |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 650 | 0 | 4 | _aUltrasonography |
| 700 | 1 | _aEvans, Gregory W | |
| 700 | 1 | _aRiley, Ward | |
| 700 | 1 | _aMeijer, Rudy | |
| 700 | 1 | _aMcBride, Karen H | |
| 700 | 1 | _aPaskett, Electra D | |
| 700 | 1 | _aHelmond, Frans A | |
| 700 | 1 | _aGrobbee, Diederick E | |
| 773 | 0 |
_tControlled clinical trials _gvol. 24 _gno. 6 _gp. 752-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0197-2456(03)00096-5 _zAvailable from publisher's website |
| 999 |
_c14395895 _d14395895 |
||